Now I have all the information needed. Let me produce the final consolidated review.

## Summary

This paper presents TrASPr, a multi-transformer architecture for tissue-specific splicing prediction, and BOS, a Bayesian optimization algorithm that uses TrASPr as an oracle to design sequences with desired splicing profiles. The model uses four separate pretrained transformers centered on each splice site of a cassette exon, combined with genomic features, to predict PSI and dPSI across conditions. The paper demonstrates strong performance on GTEx and MGP datasets, evaluates on RBP knockdown and minigene data, and shows that BOS can efficiently generate sequences meeting splicing targets in silico.

## Strengths

- **Novel multi-transformer architecture tailored to splicing biology.** Rather than applying a generic sequence model, TrASPr uses four transformers each focused on a specific splice-site region, keeping the model's attention on the most relevant local context. Ablation studies (Table 2) confirm each component contributes: removing pretraining drops Pearson R from 0.81 to 0.66, removing features drops it to 0.57, and replacing transformers with LSTMs degrades all metrics.
- **Demonstrated improvement over a feature-based model on the MGP benchmark.** On the MGP dataset with standard filtering, TrASPr significantly outperforms the AE+MLP feature model (Jha et al. 2017) on both AUROC and AUPRC for dPSI prediction (Figure 3, Table 1). This comparison uses the same train/test split and target definition, making it fair.
- **Biologically meaningful validation on independent experimental data.** TrASPr correctly predicts the direction of splicing changes for 7/9 mutations in a Daam1 minigene reporter assay (p=0.0012) and achieves statistically significant direction prediction on ENCODE RBP knockdown data (p=0.0001). These provide external validation beyond held-out test splits.
- **First explicit formulation of RNA splicing sequence design as a constrained optimization problem.** The paper formalizes the design task with edit-distance constraints and tissue-specific targets, then adapts latent-space Bayesian optimization (LSBO) to solve it, comparing favorably to random mutation and genetic algorithm baselines.

## Weaknesses

### Fatal
None.

### Major

1. **The Pangolin comparison is not a valid baseline for the SOTA claim.** Pangolin was designed for a different task (splice usage prediction across 10Kb windows, trained on data from four species) and cannot natively handle cassette exons. The adaptation described by the authors (feeding 3'/5' splice sites and averaging outputs) is not validated and likely produces an out-of-distribution evaluation. The reported 0.17 Pearson correlation may reflect this task mismatch, not a genuine performance gap. The paper's central claim of "significantly outperforming recently published models" rests in part on this comparison. While the paper is transparent about the adaptation, the claim would be better supported by dropping or replacing this comparison with a retrained model on the same task. The comparison against AE+MLP on MGP is fair and useful, but alone it does not establish SOTA across datasets.

### Minor

2. **The MGP stringent-filtering phenomenon is under-analyzed.** The paper reports that under more stringent filtering TrASPr's performance degrades while AE+MLP's improves, explaining that the removed events had labels correlated with similar training samples. However, the paper does not report: (a) how many events were removed by the stringent filter, (b) the actual performance numbers under both filters, or (c) any analysis distinguishing genuine regulatory learning from dataset artifact. The explanation given is plausible (sequence-based models naturally leverage similarity; feature-based models cannot), but the absence of quantitative transparency makes it hard to assess the severity of the effect.

3. **RBP KD validation relies on a long chain of assumptions with modest results.** The approach maps RBP knockdown to in-silico mutation of motif instances, which assumes: motifs accurately capture binding specificity, mutation of motifs fully recapitulates KD effects, and no indirect effects exist. The resulting dPSI correlation of 0.34 (p=0.019) and ~50-60% direction accuracy are modest, especially for the negative direction cases where roughly half are predicted as "no change." The paper acknowledges some of these limitations in the discussion but does not quantify how many events are affected or analyze failure cases systematically.

4. **BOS evaluation assumes the oracle is correct.** The design evaluation measures success against TrASPr's own predictions rather than against biological ground truth. The paper acknowledges this ("Note that here we assume the Oracle is correct and only assess the ability to efficiently generate candidate sequences"), and does provide some biological plausibility analysis (generated mutations cluster near splice sites and known regulatory regions). However, this limits the strength of the design contribution — it demonstrates optimization on a surrogate function, not validated RNA design.

5. **Cross-entropy loss on continuous targets is not adequately explained.** The paper states "For all of those target variables we use the cross-entropy loss function which performed better than regression" without describing how continuous values in [0,1] (PSI) and [-1,1] (dPSI) were transformed for cross-entropy computation. This is needed for reproducibility.

6. **VAE latent dimension and training hyperparameters are not specified.** The paper mentions a 6-layer Transformer encoder/decoder but does not give the latent dimensionality d, training hyperparameters (learning rate, batch size, epochs), or whether any β-VAE weighting was used. Given that the VAE is a core component of BOS, these details matter for reproducibility.

### Trivial

7. "TNOM" (used in the p-value for the RBP KD direction test, Section 4.3) is not defined anywhere in the paper.

## Nice-to-Haves

- A quantitative table of performance under both the standard and stringent MGP filters, with event counts, would clarify the generalization concern.
- VAE details (latent dimension, training hyperparameters) would aid reproducibility.
- Clarification of how cross-entropy is applied to continuous regression targets.

## Removed Points

These points were flagged by reviewers but are not included as weaknesses in the main review:

- **"The threshold for significance (95th percentile of random mutations) is set on the same set of events used for validation, which could produce a biased null."** — This is not a valid criticism. Using random mutations on the same exons (excluding motif regions) to construct the null is standard practice: it controls for exon-specific properties (length, GC content, baseline inclusion level) that would confound a cross-exon null. This is methodologically correct, not biased.
- **"The VAE may lead to data splitting issues because trained on the same set as TrASPr."** — The paper states the VAE is trained "leveraging the same data used to train TrASPr." This is standard for LSBO and does not create a data-splitting problem since the VAE is an unsupervised model (sequence reconstruction), not a supervised predictor on the same labels.
- **Generic formatting/style nitpicks** are removed per the hard rules.

## Novel Insights

None beyond the paper's own contributions. The reviews surface legitimate methodological concerns (particularly about the Pangolin comparison) but do not offer a novel re-interpretation of the paper's results or approach.

## Suggestions

1. **Address the Pangolin comparison.** Either retrain Pangolin on the same cassette-exon PSI prediction task with the same data, or replace this comparison with a more defensible baseline (e.g., a SpliceAI-based model retrained on this task). The current adaptation is not publishable as evidence of SOTA.
2. **Report quantitative filter analysis.** Provide a table showing the number of events removed by the stringent MGP filter and the performance of both TrASPr and AE+MLP under both filter settings.
3. **Clarify the cross-entropy loss.** Describe how continuous PSI/dPSI targets are transformed for cross-entropy computation (e.g., discretization into bins, or treated as probabilities for a binary classification framing).
4. **Report VAE architectural details.** Specify the latent dimension size and training hyperparameters for the VAE used in BOS.
5. **Define TNOM** or replace it with a standard test name.

## Score and Decision

This paper tackles an important problem with a well-motivated architecture and provides multiple lines of evaluation. However, the central SOTA claim is weakened by a problematic comparison to Pangolin that conflates task mismatch with model capability. The remaining evidence (AE+MLP comparison, ablation studies, minigene validation) shows genuine promise, but the Pangolin issue is substantive enough that the paper's headline claims require revision. The BOS contribution, while novel in task formulation, is limited by surrogate-only evaluation. With major revision — particularly around the Pangolin baseline — the paper could be competitive.

MY FINAL SCORE: <pineapple>5.5</pineapple>
MY FINAL DECISION: <orange>Reject</orange>